Published Manuscripts (2017)

Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye K. The PRIME Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. Value in Health 2017; 20(7): 985-91.

Russell-Jones D, Heller S, Buchs S, Sandberg A, Valentine WJ, Hunt B. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. Diabetes, Obesity and Metabolism 2017; 19(12): 1773-80.

Kvapil M, Prázný M, Holik P, Rychna K, Hunt B. Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. Diabetes Therapy 2017; 8(6): 1331-47.

Hunt B, McConnachie CC, Gamble C, Dang-Tan T. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. Journal of Medical Economics 2017; 20(11): 1117-20.

Psota M, Psenkova MB, Racekova N, Ramirez de Arellano A, Vandebrouck T, Hunt B. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak Health System. ClinicoEconomics and Outcomes Research 2017; 9: 749–62.

Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opinion on Drug Delivery 2017; 14(12): 1439-46.

Hunt B, Glah D, van der Vliet M. Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands. Diabetes Therapy 2017; 8(4): 753-65.

Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. ClinicoEconomics and Outcomes Research 2017; 9: 475-83.

Hunt B, Ye Q, Valentine WJ, Ashley D. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. Diabetes Therapy 2017; 8(1): 129-47.

Roze S, de Portu S, Smith-Palmer J, Delbaere A, Valentine W, Ridderstrale M. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. Diabetes Research and Clinical Practice 2017; 128: 6-14

Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes, Obesity and Metabolism 2017; 19(6): 842-9.

Mezquita-Raya P, Ramírez de Arellano A, Kragh N, Vega-Hernandez G, Pöhlmann J, Valentine WJ, Hunt B. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy 2017; 8(2): 401-15.

Hunt B, Mocarski, M, Valentine WJ, Langer J. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Advances in Therapy 2017; 34(4): 954-65.

Saunders R, Struys MMRF, Pollock RF, Mestek M, Lightdale JR. Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis. BMJ Open 2017;7(6):e013402.

Hunt B, Mocarski, M, Valentine WJ, Langer J. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Journal of Medical Economics 2017; 20(7): 663-70.

Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Journal of Medical Economics 2017; 20(3): 213-20.

Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy 2017; 8(3): 531-44.

Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R. Long-Term Cost-Effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Clinical Therapeutics 2017;39(7):1347-59.

Close phone HUD
+41 61 271 6214
Dial with SkypeOutDial with SkypeOut
Close phone HUD
+41 79 340 4644
Dial with SkypeOutDial with SkypeOut